Leptomeningeal metastases
Updates to Article Attributes
Leptomeningeal metastases, also know as carcinomatous meningitis, refers to the spread of malignant cells through the CSF space. These cells can be originated both inoriginate from primary CNS tumours (e.g. drop-metastases), as well as from distant tumours that have metastasised via haematogenous spread.
This article has a focus on subarachnoid space involvement. Please refer onRefer to intradural extramedullary metastases for a particular discussion related to theof leptomeningeal metastases in the spine. For other intracranial metastatic locations, please refer to the main article on intracranial metastases.
Epidemiology
The demographics follow those of the underlying malignancy.
Clinical presentation
Clinical presentation is varied, but most commonly includes a headache, spine or radicular limb pain or sensory abnormalities, nausea and vomiting, and focal neurological deficits 3. Meningism is only present in a minority of patients (13% 3).
Pathology
The primary intracerebral malignancies that may cause metastases to the subarachnoid space are:
- glioblastoma (GBM) and anaplastic astrocytoma
- medulloblastoma
- sPNET
- ependymoma
- germinoma
- choroid plexus carcinoma
The vast majority of leptomeningeal metastases originates fromoccur in the context of a widespread metastatic disease (haematogenous, likely by haematogenous spread. Over 50% of cases have concurrent brain (parenchymal) metastases 13. The most common primary sites are:
-
breast cancer
: most common(particularly infiltrating lobular carcinoma) -
lung cancer
: most common - melanoma
lymphomaleukaemia- gastrointestinal (gastric carcinoma4,5, colorectal cancer8)
- hematologic: lymphoma / leukaemia
Less common, but reported primary sites include:
- pancreatic carcinoma 6
- ovarian cancer 7
-
colorectal cancer8 - renal cell cancer 9
- carcinoma of the uterine cervix 10
- adrenal cortical carcinoma 11
- oesophageal cancer 12
Radiographic features
MRI
- T1: usually normal
- T1 C+ (Gd): leptomeningeal enhancement is the primary mode of diagnosis, often scattered over the brain in a 'sugar coated' manner
- T2: usually normal
-
FLAIR
- abnormally elevated signal within sulci 2
- can be performed both non-contrast and post-contrast, but is slightly less specific if performed post-contrast 1
Treatment and prognosis
Untreated leptomeningealLeptomeningeal metastases have a poor prognosis with patients usually succumbing within a few months, whereas, with (median overall survival 2.4 months 13). With treatment, that time may be extended up to 6-10 months 2,3. Treatment can consist of 3:
- intrathecal chemotherapy
- radiotherapy
Resection is usually inappropriate due to the presence of widespread metastases.
Differential diagnosis
- leptomeningeal inflammation: leptomeningitis
- slow flow in vessels
- propofol, high oxygen tension, subarachnoid blood can all elevate sulcal FLAIR signal
-<p><strong>Leptomeningeal metastases</strong>, also know as <strong>carcinomatous meningitis</strong>, refers to the spread of malignant cells through the CSF space. These cells can be originated both in primary CNS tumours (e.g. <a href="/articles/leptomeningeal-drop-metastases">drop-metastases</a>), as well as from distant tumours that have metastasised via haematogenous spread.</p><p>This article has a focus on subarachnoid space involvement. Please refer on <a href="/articles/intradural-extramedullary-metastases">intradural extramedullary metastases</a> for a particular discussion related to the leptomeningeal metastases in the spine. For other intracranial metastatic locations, please refer to the main article on <a href="/articles/intracranial-metastases">intracranial metastases</a>. </p><h4>Epidemiology</h4><p>The demographics follow those of the underlying malignancy.</p><h4>Clinical presentation</h4><p>Clinical presentation is varied, but most commonly includes a headache, spine or radicular limb pain or sensory abnormalities, nausea and vomiting, and focal neurological deficits <sup>3</sup>. Meningism is only present in a minority of patients (13% <sup>3</sup>).</p><h4>Pathology</h4><p>The primary intracerebral malignancies that may cause metastases to the subarachnoid space are:</p><ul>- +<p><strong>Leptomeningeal metastases</strong>, also know as <strong>carcinomatous meningitis</strong>, refers to the spread of malignant cells through the CSF space. These cells can originate from primary CNS tumours (e.g. <a href="/articles/leptomeningeal-drop-metastases">drop-metastases</a>), as well as from distant tumours that have metastasised via haematogenous spread.</p><p>This article has a focus on subarachnoid space involvement. Refer to <a href="/articles/intradural-extramedullary-metastases">intradural extramedullary metastases</a> for a discussion of leptomeningeal metastases in the spine. For other intracranial metastatic locations, please refer to the main article on <a href="/articles/intracranial-metastases">intracranial metastases</a>. </p><h4>Epidemiology</h4><p>The demographics follow those of the underlying malignancy.</p><h4>Clinical presentation</h4><p>Clinical presentation is varied, but most commonly includes a headache, spine or radicular limb pain or sensory abnormalities, nausea and vomiting, and focal neurological deficits <sup>3</sup>. Meningism is only present in a minority of patients (13% <sup>3</sup>).</p><h4>Pathology</h4><p>The primary intracerebral malignancies that may cause metastases to the subarachnoid space are:</p><ul>
-</ul><p>The vast majority of leptomeningeal metastases originates from a widespread metastatic disease (haematogenous spread). The most common primary sites are: </p><ul>- +</ul><p>The vast majority of leptomeningeal metastases occur in the context of a widespread metastatic disease, likely by haematogenous spread. Over 50% of cases have concurrent brain (parenchymal) metastases <sup>13</sup>. The most common primary sites are: </p><ul>
-<a href="/articles/breast-cancer">breast cancer</a>: most common</li>-<li>-<a href="/articles/lung-cancer-3">lung cancer</a>: most common</li>- +<a href="/articles/breast-cancer">breast cancer</a> (particularly <a title="Infiltrating lobular carcinoma" href="/articles/invasive-lobular-carcinoma-of-the-breast">infiltrating lobular carcinoma</a>)</li>
- +<li><a href="/articles/lung-cancer-3">lung cancer</a></li>
-<li><a href="/articles/lymphoma">lymphoma</a></li>-<li><a href="/articles/leukaemia">leukaemia</a></li>-<li>-<a href="/articles/gastric-adenocarcinoma">gastric carcinoma</a> <sup>4,5</sup>- +<li>gastrointestinal (<a href="/articles/gastric-adenocarcinoma">gastric carcinoma</a> <sup>4,5</sup>, <a href="/articles/colorectal-carcinoma">colorectal cancer</a> <sup>8</sup>)</li>
- +<li>hematologic: <a href="/articles/lymphoma">lymphoma</a> / <a href="/articles/leukaemia">leukaemia</a>
- +</ul><p>Less common, but reported primary sites include:</p><ul>
-<a href="/articles/colorectal-carcinoma">colorectal cancer</a> <sup>8</sup>-</li>-<li>-<li> <a href="/articles/carcinoma-of-the-uterine-cervix">carcinoma of the uterine cervix </a><sup>10</sup>- +<li>
- +<a href="/articles/carcinoma-of-the-uterine-cervix">carcinoma of the uterine cervix </a><sup>10</sup>
-<li> <a href="/articles/adrenal-cortical-carcinoma-1">adrenal cortical carcinoma</a> <sup>11</sup>- +<li>
- +<a href="/articles/adrenal-cortical-carcinoma-1">adrenal cortical carcinoma</a> <sup>11</sup>
-<li> <a title="Oesophageal cancer" href="/articles/oesophageal-carcinoma-1">oesophageal cancer</a> <sup>12</sup>- +<li>
- +<a href="/articles/oesophageal-carcinoma-1">oesophageal cancer</a> <sup>12</sup>
-</ul><h4>Treatment and prognosis</h4><p>Untreated leptomeningeal metastases have a poor prognosis with patients usually succumbing within a few months, whereas, with treatment, that time may be extended up to 6-10 months <sup>2,3</sup>. Treatment can consist of <sup>3</sup>:</p><ul>- +</ul><h4>Treatment and prognosis</h4><p>Leptomeningeal metastases have a poor prognosis with patients usually succumbing within a few months (median overall survival 2.4 months <sup>13</sup>). With treatment, that time may be extended up to 6-10 months <sup>2,3</sup>. Treatment can consist of <sup>3</sup>:</p><ul>
-</ul><h4>Differential diagnosis</h4><ul>- +</ul><p>Resection is usually inappropriate due to the presence of widespread metastases.</p><h4>Differential diagnosis</h4><ul>
References changed:
- 13. Clarke J, Perez H, Jacks L, Panageas K, Deangelis L. Leptomeningeal Metastases in the MRI Era. Neurology. 2010;74(18):1449-54. <a href="https://doi.org/10.1212/WNL.0b013e3181dc1a69">doi:10.1212/WNL.0b013e3181dc1a69</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/20439847">Pubmed</a>